Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer.
Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer.
复制标题
DOI：
10.18632/oncotarget.24617
复制
发表时间：
2018-04-10
期刊：
影响因子：
--
通讯作者：
Ishioka C
中科院分区：
文献类型：
--
作者：
Okita A;Takahashi S;Ouchi K;Inoue M;Watanabe M;Endo M;Honda H;Yamada Y;Ishioka C
共有分子亚型（CMS）分类是基于综合基因表达谱的最可靠的结直肠癌（CRC）分类之一。本研究旨在阐明CMS是否是转移性CRC（mCRC）标准化疗疗效的预测因素。我们回顾性纳入了193例mCRCs患者，并使用综合基因表达数据将其分为4种亚型：CMS 1-CMS 4。分析各亚型与治疗结果之间的关系。关于一线化疗，在CMS 4中，基于伊立替康（IRI）的化疗在无进展生存期（PFS;风险比[HR] = 0. 31，95%置信区间[CI] 0. 13 - 0. 64）和总生存期（OS; HR = 0. 45，95% CI 0. 19 - 0. 99）方面显著上级基于奥沙利铂（OX）的化疗。关于抗表皮生长因子受体（抗EGFR）治疗，CMS 1显示PFS尤其差（HR = 2.50，95% CI 1.31-4.39）和OS（HR = 4.23，95% CI 1.83-9.04），与其他亚型相比，CMS 2显示出特别好的PFS（HR = 0.67，95% CI 0.44-1.01）和OS（HR = 0.49，95% CI 0.27-0.87）。CMS的生物学特性可能影响化疗的疗效。CMS可能是化疗对mCRC疗效的一个新的预测因子。
The consensus molecular subtypes (CMS) classification is one of the most robust colorectal cancer (CRC) classifications based on comprehensive gene expression profiles. This study aimed to clarify whether the CMS is a predictive factor for therapeutic effects of standard chemotherapies for metastatic CRC (mCRC). We retrospectively enrolled 193 patients with mCRCs, and using comprehensive gene expression data, classified them into 4 subtypes: CMS1–CMS4. The associations between the subtypes and treatment outcomes were analyzed. Regarding first-line chemotherapy, irinotecan (IRI)-based chemotherapy was significantly superior to oxaliplatin (OX)-based chemotherapy for progression-free survival (PFS; hazard ratio [HR] = 0.31, 95% confidence interval [CI] 0.13–0.64) and overall survival (OS; HR = 0.45, 95% CI 0.19–0.99) in CMS4. Regarding the anti-epidermal growth factor receptor (anti-EGFR) therapy, CMS1 showed particularly worse PFS (HR = 2.50, 95% CI 1.31–4.39) and OS (HR = 4.23, 95% CI 1.83–9.04), and CMS2 showed particularly good PFS (HR = 0.67, 95% CI 0.44–1.01) and OS (HR = 0.49, 95% CI 0.27–0.87) compared with the other subtypes. The biological characteristics of CMS may influence the efficacy of chemotherapy. CMS might be a new predictive factor for the efficacy of chemotherapy against mCRCs.